2012 Annual Report Bristol-Myers Squibb  3 a leader in the field of oncology and  a pioneer in the new, increasingly  promising field of immuno-oncology. With respect to hepatitis C, we were disappointed about the need to  discontinue the BMS-986094 clinical  program, but in the interest of patient  safety, we acted swiftly to end it.  Despite this situation, our hepatitis  C portfolio remains significant. We  made important progress on an  oral dual-regimen in development in  Japan, where we plan to file a regula- tory submission in 2013, and we  intensified our focus on the Phase II  development of an all-oral triple regi- men, preparing the way for Phase III  trials in 2014. Central to our transformation and  a key to our ongoing success has  been an active focus on continuous  improvement, particularly through  enhanced productivity and forward- looking changes to our organization. In 2012, we began implementing a  new global structure – one better  suited for our increasingly diversified  portfolio and geographical emphasis.  This included a restructuring of our  U.S. and European operations as well  as our approach to global markets. We also launched the Enterprise  Services organization, an effort to  streamline internal operations, and we  unveiled a new, cutting-edge Plant  Network Strategy in our manufactur- ing organization. To my Senior Management Team I welcomed three new executives in  2012 and one more early in 2013. Promoted from within our company  were John Elicker (Public Affairs and  For communities, our commitment  expressed itself through our contin- For patients, our commitment includes  our work in the laboratory to discover  and develop innovative new medicines  as well as our work in the field to  promote access to them. We there- fore focus a great deal of time and  resources also making access a reality  for people living in the most challeng- ing circumstances. In 2012, that meant  expanding our U.S.-based  Together  on Diabetes  program – which began  in 2010 with a $100 million grant – to  China and India, two countries with  the largest populations of diabetic  patients. It also meant completing the first successful phase of our five-country collaboration with the  WHO concerning the HIV/tuberculo- sis epidemic in sub-Saharan Africa,  an initiative that represents an exten- sion of our landmark  SECurE THE  FuTurE  program.  After all, people are at the center  of everything we do. People who  depend on our innovative medicines. People who live in our communities. People who work for our company. Our commitment is to them and their  families, and in 2012, this was dem- onstrated in compelling ways. Individually and collectively, these  organizational changes are all  designed to help us to do our work  faster, smarter and better – to deliver  the promise of our portfolio more  effectively and efficiently – and to  impact positively the lives of people  around the world. Investor Relations) and Samuel Moed  (Strategic Planning and Analysis). Recruited to our company were  Frances Heller (Business Develop- ment) and Ann Powell Judge (Human  Resources). ued work with the United Nations  Global Compact and with our own  Go Green and Earth Day initiatives. These efforts – combined with the  progress made on our Sustainability  2015 Goals – contributed to our top  designation on the 2012 Corporate  Responsibility magazine’s 100 Best  Corporate Citizens list.  For employees, our commitment was  clear in the work we did to develop,  enrich and recognize our people. We reaffirmed our longstanding  adherence to equal opportunity prin- ciples and rededicated ourselves to  maintaining a work environment that  values diversity and that embodies  fairness, equity and respect. Once  again, we placed an emphasis on  maintaining an atmosphere designed  to promote a good work product and  a good work experience. Clearly, we are in a strong position.  Our BioPharma Transformation has  been a journey during which we have  worked through many challenges and  seized many opportunities. We have  been finding our way through the  losses of exclusivity. We have been  adapting to the “new normal” of global economic uncertainty. And we  have just completed an important year  of transition – one that underscored the potential of our increasingly  diversified portfolio and pipeline of  innovative medicines. All of this enables us to bring new  possibilities to patients. March 11, 2013 Lamberto Andreotti Chief Executive Officer Our Steadfast Commitment Our Improved Organization Hepatitis C